文献速递泌尿男性生殖肿瘤

血浆DNA中雄激素受体基因状态与去势抵抗性前列腺癌患者接受恩扎卢胺或阿比特龙治疗的不良预后相关:一项多机构相关性生物标志物研究

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
PubMed 文献 · Ann Oncol · 2017-01-01

该多机构回顾性生物标志物研究采用多重微滴数字PCR检测血浆DNA中雄激素受体(AR)基因状态,发现血浆AR扩增与去势抵抗性前列腺癌患者接受恩扎卢胺或阿比特龙治疗后的更差总生存、无进展生存及PSA缓解率相关,血浆AR为独立预后因子,结论需前瞻性评估基于血浆AR的治疗决策。

要点

  • 血浆AR扩增者接受恩扎卢胺或阿比特龙后总生存与无进展生存更差。
  • 血浆AR扩增与PSA下降≥50%的比例更低相关。
  • 血浆AR是两队列中预后的独立预测因子。

核心结论

  • 采用微滴数字PCR评估血浆AR状态可识别对恩扎卢胺或阿比特龙治疗反应更差的去势抵抗性前列腺癌患者,作者认为现在需要前瞻性评估基于血浆AR的治疗决策。

研究设计与样本

  • 回顾性分析三个生物标志物方案中前瞻性收集临床数据的患者血浆DNA,采用多重微滴数字PCR检测AR拷贝数与突变。
  • 主要队列包括73例未接受化疗和98例多西他赛治疗后接受恩扎卢胺或阿比特龙治疗的去势抵抗性前列腺癌患者。
  • 次要队列为PREMIERE试验中94例接受恩扎卢胺治疗的未化疗患者。

主要发现

  • 主要队列中,未化疗患者AR扩增10例(14%),多西他赛治疗后患者33例(34%)。
  • 主要队列中,未化疗患者AR扩增与更差OS相关(HR 3.98;95%CI 1.74-9.10;P<0.001),多西他赛治疗后患者AR扩增与更差OS相关(HR 3.81;95%CI 2.28-6.37;P<0.001)。
  • 主要队列中,未化疗患者AR扩增与更差PFS相关(HR 2.18;95%CI 1.08-4.39;P=0.03),多西他赛治疗后患者AR扩增与更差PFS相关(HR 1.95;95%CI 1.23-3.11;P=0.01)。
  • 主要队列中,未化疗患者AR扩增与PSA下降≥50%率相关(OR 4.7;95%CI 1.17-19.17;P=0.035),多西他赛治疗后患者AR扩增与PSA下降≥50%率相关(OR 5.0;95%CI 1.70-14.91;P=0.003)。
  • 多西他赛治疗后接受阿比特龙治疗患者中8例(11%)观察到AR突变[2105T>A(p.L702H)和2632A>G(p.T878A)],未化疗接受阿比特龙治疗患者中未观察到,AR突变与更差OS相关(HR 3.26;95%CI 1.47-未达到;P=0.004)。

临床怎么用

  • 作者认为现在需要前瞻性评估基于血浆AR的治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. METHODS: We optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial). RESULTS: In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74-9.10; P < 0.001 and HR 3.81; 95% CI 2.28-6.37; P < 0.001, respectively], PFS (HR 2.18; 95% CI 1.08-4.39; P = 0.03, and HR 1.95; 95% CI 1.23-3.11; P = 0.01, respectively) and rate of PSA decline ≥50% [odds ratio (OR), 4.7; 95% CI 1.17-19.17; P = 0.035 and OR, 5.0; 95% CI 1.70-14.91; P = 0.003, respectively]. AR mutations [2105T>A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47-not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94-9.68; P < 0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26-19.93; P < 0.001) and OS (HR 11.08; 95% CI 2.16-56.95; P = 0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts. CONCLUSION: Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. CLINICAL TRIAL NUMBER: NCT02288936 (PREMIERE trial).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Conteduca V, Wetterskog D, Sharabiani MTA, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017. PMID: 28472366. doi:10.1093/annonc/mdx155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。